106 related articles for article (PubMed ID: 22542194)
1. Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.
Boys ML; Bian F; Kramer JB; Chio CL; Ren XD; Chen H; Barrett SD; Sexton KE; Iula DM; Filzen GF; Nguyen MN; Angell P; Downs VL; Wang Z; Raheja N; Ellsworth EL; Fakhoury S; Bratton LD; Keller PR; Gowan R; Drummond EM; Maiti SN; Hena MA; Lu L; McConnell P; Knafels JD; Thanabal V; Sun F; Alessi D; McCarthy A; Zhang E; Finzel BC; Patel S; Ciotti SM; Eisma R; Payne NA; Gilbertsen RB; Kostlan CR; Pocalyko DJ; Lala DS
Bioorg Med Chem Lett; 2012 May; 22(10):3392-7. PubMed ID: 22542194
[TBL] [Abstract][Full Text] [Related]
2. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
[TBL] [Abstract][Full Text] [Related]
10. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
11. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Anderton MJ; Mellor HR; Bell A; Sadler C; Pass M; Powell S; Steele SJ; Roberts RR; Heier A
Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
Kim DK; Choi JH; An YJ; Lee HS
Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
[TBL] [Abstract][Full Text] [Related]
14. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
17. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model.
Terashima H; Kato M; Ebisawa M; Kobayashi H; Suzuki K; Nezu Y; Sada T
Eur J Pharmacol; 2014 Jul; 734():60-6. PubMed ID: 24726873
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jung SH; Lee HS; Dewang PM
Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
20. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
